OBJECTIVES: Nowadays hospital at home (HAH) is dealing with increasing demand of the population to be treated at home and government commitment to promote its development. A brake identified for its growth is its funding system based on price per activity. The funding of expensive drugs is a current concern. This present study about oral anti-cancer drugs (OACD) in the Hospital at Home, Assistance Publique – Hôpitaux de Paris (HAH AP-HP) in 2014 aims to determine if the cost of OACD is too high compared to the costs of the respective tariff stays. METHODS: Patients with OACD delivery at HAH AP-HP in 2014 are identified and all tariffs datas relating to their stays are extracted. Treatment costs and stays tariffs are calculated to determine ratio cost of treatment /stay tariff per stay. Moreover, another ratio is calculated with national datas from the 2013 costs survey for the same tariff combinations that HAH AP-HP stays. The influential parameters on the HAH AP-HP ratio are determined by multivariate analysis and both HAH and national ratios are compared. RESULTS: On 2014, the HAH AP-HP stays with a treatment cost of 30% or more per stay (criteria for total funding in addition to the HAH tariffs) are estimated at 17% (42 of 241). However, the ratio can exceed 100% for a few stays (6). Multivariate analysis reveals two important parameters influencing significantly the HAH ratio: male status and drug special supervision status. About the comparison with the national ratio, the main difference is the extreme values above 100%, less numerous for the national ratio. CONCLUSIONS: These results illustrate the difficulties to finance certain drugs in HAH tariff. The creation of a specific funding for these drugs could be a solution to achieve the goal of doubling HAH activity set by the Health Ministry in France.